Home > Boards > US Listed > Medical - Equipment > Cytosorbents Corporation (CTSO)

Cytosorb use to slow the aging process and

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
techxen Member Profile
 
Followed By 12
Posts 491
Boards Moderated 0
Alias Born 08/03/13
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/26/2021 6:11:44 PM
CytoSorbents to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum and Jefferies London Healthcare Conference PR Newswire (US) - 11/15/2021 4:30:00 PM
Cytosorbents EPS misses by $0.03, beats on revenue Seeking Alpha - 11/4/2021 4:29:11 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/4/2021 4:15:41 PM
CytoSorbents Reports Full Third Quarter 2021 Financial and Operational Results PR Newswire (US) - 11/4/2021 4:15:00 PM
Cytosorbents Q3 2021 Earnings Preview Seeking Alpha - 11/3/2021 5:35:41 PM
CytoSorbents Comments on REMOVE Study Presentation PR Newswire (US) - 10/20/2021 7:05:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/15/2021 6:26:17 AM
First Patient Enrolled in U.S. STAR-T Pivotal Trial Evaluating the DrugSorb-ATR™ Antithrombotic Removal System to Remove Ticagrelor During Cardiothoracic Surgery PR Newswire (US) - 10/14/2021 7:05:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/13/2021 7:01:40 AM
CytoSorbents Receives Full FDA Investigational Device Exemption (IDE) Approval to Begin U.S. STAR-D Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR™ Antithrombotic Removal System During Urgent Cardiothoracic Surgery PR Newswire (US) - 10/12/2021 4:38:00 PM
CytoSorbents Provides Preliminary Third Quarter Business Update and Revised 2021 Product Revenue Guidance PR Newswire (US) - 10/12/2021 4:35:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/8/2021 7:31:48 AM
CytoSorbents Announces Availability of Preliminary Data Abstracts from Two Endocarditis Studies, including the REMOVE study, to be Presented at the EACTS Conference PR Newswire (US) - 10/7/2021 3:11:00 PM
Merus, Nutriband leads healthcare gainers; Osmotica Pharmaceuticals, Prelude Therapeutics among major losers Seeking Alpha - 10/7/2021 10:59:16 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/14/2021 5:01:28 PM
CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb® in Critically Ill Patients with COVID-19 PR Newswire (US) - 9/14/2021 9:25:00 AM
CytoSorbents Commemorates World Sepsis Day and Sepsis Awareness Month with Key Sepsis-Related Events, Sponsorships and Studies PR Newswire (US) - 9/13/2021 7:08:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/10/2021 4:33:48 PM
CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for the U.S. Clinical Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR™ Antithrombotic Removal System During Urgent Cardiothoracic Surgery PR Newswire (US) - 9/10/2021 7:08:00 AM
CytoSorbents Announces Webinar Discussing Topline Results from the U.S. CTC Registry using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO) PR Newswire (US) - 9/8/2021 4:15:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/1/2021 5:28:08 PM
SKLZ, RUN and AMBA among pre market gainers Seeking Alpha - 9/1/2021 8:19:50 AM
Topline Results from CytoSorbents' U.S. CTC Multicenter Registry Demonstrate High Survival using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO) PR Newswire (US) - 9/1/2021 7:08:00 AM
CytoSorbents and Aferetica Announce the Commercial Launch in Italy of the PerSorb™ Adsorber and PerLife™ Organ Perfusion System, respectively, at the European Society of Organ Transplantation Congress PR Newswire (US) - 8/30/2021 7:08:00 AM
techxen   Tuesday, 06/30/20 10:52:48 AM
Re: None
Post # of 26883 
Cytosorb use to slow the aging process and progression of degenerative diseases?

The company just had a new patent published this month, for removing advanced glycation end products (AEG's) from a bodily fluids.

REDUCTION OF ADVANCED GLYCATION ENDPRODUCTS FROM BODILY FLUIDS
http://www.freepatentsonline.com/y2020/0188427.html

There is a lot to adsorb in this patent (no pun intended), but I will try and highlight a few things that stood out to me:

--------------------------------------------------------------

- Advanced glycation end products (AGEs) are proteins or lipids that become glycated as a result of exposure to sugars in the body. They are a bio-marker implicated in aging and the development, or worsening, of many degenerative diseases.

- These degenerative diseases as well as aging are mainly based on a life-long accumulation of molecular damages within molecules, cells and tissues caused by these advanced glycation end products (AGEs).

- High levels of AGEs have been linked with the development of a variety of diseases including diabetes, heart disease, kidney failure, Alzheimer's and macular degeneration.

- There is a need for methods that treat, prevent or low the progression of diseases associated with AGEs.

- (This is where things get interesting) - One application is where blood or other bodily fluid is pumped out of the body, directly through a CytoSorb™ hemoperfusion cartridge where the beads remove AGEs, and the purified fluid is then pumped back into the body. "Other bodily fluids" include saliva, nasopharyngeal fluid, blood, plasma, serum, saliva, gastrointestinal fluid, bile, cerebrospinal fluid, pericardial, vaginal fluid, seminal fluid, prostatic fluid, peritoneal fluid, pleural fluid, urine, synovial fluid, interstitial fluid, intracellular fluid, extracellular fluid, lymph, mucus, or vitreous humor.

- The patent refers to other embodiments (implementations) which address how the sorbent may be formulated - for example, a powder, a tablet, a capsule, a solution, a slurry, an emulsion, a suppository, or in a food substance. The sorbent may be packaged in portable bottles, vials, blister packs, bags, pouches, or other container that allows for either single or multiple dosages. It also refers to other ways the sorbent can be delivered or administered besides extracorporeal - for example given orally, rectally, via a feeding tube, subcutaneous or transdermal delivery, or topical.

--------------------------------------------------------------

If you are not familiar with AGE's, read this article when you have a chance, it explains everything you want to know about AGE's in layman terms:
"AGEs DamAGE Our Bodies"
http://longevityfacts.com/ages-damage-bodies-advanced-glycation-end-products/

Medical science has yet to invent a magic pill or potion that cleans a significant portion of AGEs from the body. There are drugs and enzymes being tested for use against AGEs but it's proving quite difficult as most drugs and enzymes will attempt to block the cell receptors that AGEs utilize to cause damage in the body. Although there is a lot of research with good prospects there is still to my limited research and knowledge no adequate drugs or therapies to get rid of advanced glycation end-products.

I would ask if there are those with a scientific or medical background to read this patent when they have time and also provide additional insights, because on the surface this looks to be an entirely new product that could come out of this and an entirely new market which is just mind boggling.



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences